Diametric Capital LP Acquires 11,886 Shares of ASP Isotopes Inc. (NASDAQ:ASPI)

Diametric Capital LP grew its holdings in ASP Isotopes Inc. (NASDAQ:ASPI) by 4.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 303,855 shares of the company’s stock after acquiring an additional 11,886 shares during the period. ASP Isotopes accounts for approximately 0.9% of Diametric Capital LP’s holdings, making the stock its 21st largest position. Diametric Capital LP owned about 0.43% of ASP Isotopes worth $1,376,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Hanson & Doremus Investment Management acquired a new stake in shares of ASP Isotopes in the 4th quarter valued at $27,000. Avantax Advisory Services Inc. acquired a new stake in shares of ASP Isotopes in the fourth quarter worth about $45,000. SVB Wealth LLC bought a new stake in shares of ASP Isotopes during the 4th quarter worth about $49,000. Boston Financial Mangement LLC acquired a new position in shares of ASP Isotopes during the 4th quarter valued at about $50,000. Finally, LPL Financial LLC bought a new position in shares of ASP Isotopes in the 4th quarter valued at approximately $54,000. Institutional investors and hedge funds own 16.80% of the company’s stock.

ASP Isotopes Stock Up 12.2 %

ASPI opened at $4.69 on Tuesday. ASP Isotopes Inc. has a twelve month low of $1.86 and a twelve month high of $9.33. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.54 and a current ratio of 7.55. The business has a 50 day moving average price of $4.99 and a 200 day moving average price of $4.95. The firm has a market cap of $334.82 million, a P/E ratio of -7.69 and a beta of 3.66.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.